Meiragtx Holdings (MGTX) AI Stock Analysis

• Market Cap: $532.82M
• Dividend Yield: N/A
• Average Volume (3M): 591.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.72
• Revenue Growth: 203.23%
• EPS Growth: -80.71%
• Country: US
• Employees: 375
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -0.51
• Shares Outstanding: 80,365,360
• 10 Day Avg. Volume: 487,386
• 30 Day Avg. Volume: 591,219
• PEG Ratio: -0.02
• Price to Book (P/B): 2.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 21.51
• Enterprise Value/Ebitda: -0.52
• 1Y Price Target: $25.67
• Price Target Upside: 287.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 59 Neutral
• Price Target: $7.00 ▲(5.58%Upside)

MeiraGTx Holdings' score reflects a mix of financial instability typical of early-stage biotech firms and recent strategic advantages. The technical analysis shows bullish momentum, while corporate events provide a significant positive outlook with FDA designation and a strategic joint venture. Valuation remains a concern due to negative earnings.

Meiragtx Holdings Business Overview & Revenue Model

Company Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

How the Company Makes Money

MeiraGTx Holdings makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue through collaborative agreements, licensing arrangements, and milestone payments from partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve co-development and commercialization efforts, allowing MeiraGTx to leverage external resources and expertise while receiving financial support. Additionally, as the company advances its product candidates through clinical trials and towards market approval, it may receive research funding and grants to support its development activities. Revenue growth is also expected to come from the eventual commercialization of its gene therapy products once they receive regulatory approval.

Meiragtx Holdings Financial Statement Overview

Summary

MeiraGTx Holdings faces typical financial challenges for early-stage biotech firms, with ongoing operating losses and reliance on external funding. Despite some revenue growth and improved leverage, profitability metrics remain negative. The balance sheet reflects financial instability with declining equity.

Income Statement

Meiragtx Holdings has shown a modest revenue growth with a TTM revenue of $34.51M, up from $33.28M in 2024. However, the company continues to face significant profitability challenges, with negative EBIT and EBITDA margins indicating operating losses. The net profit margin remains negative, underscoring ongoing financial losses, which is a common challenge in the biotechnology sector as companies invest heavily in R&D.

Balance Sheet

The company's debt-to-equity ratio has improved, reflecting a reduced leverage position. However, the equity ratio has decreased, indicating a lower proportion of equity funding relative to total assets. Despite a positive net debt position, the overall financial stability remains a concern due to declining stockholders' equity and substantial liabilities.

Cash Flow

Meiragtx Holdings' cash flow situation shows significant negative free cash flow, driven by high capital expenditures and negative operating cash flow. While there has been an influx of cash from financing activities, the reliance on external funding could pose sustainability issues in the long term. The operating cash flow to net income ratio reflects the ongoing cash burn typical in early-stage biotech firms.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
34.51M	33.28M	14.02M	15.92M	37.70M	15.56M
	Gross Profit
12.61M	9.49M	14.02M	7.20M	29.83M	15.56M
	EBIT
-159.04M	-164.21M	-137.06M	-116.36M	-73.19M	-62.55M
	EBITDA
-141.78M	-121.69M	-57.05M	-115.95M	-71.40M	-53.68M
	Net Income Common Stockholders
-167.33M	-147.79M	-84.03M	-142.88M	-71.98M	-53.96M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
66.52M	103.66M	129.57M	115.52M	137.70M	209.52M
	Total Assets
224.01M	269.75M	326.74M	318.24M	320.16M	363.70M
	Total Debt
3.30M	84.80M	89.26M	92.25M	23.73M	22.25M
	Net Debt
-63.23M	-18.86M	-40.30M	-23.27M	-113.97M	-187.27M
	Total Liabilities
190.91M	201.92M	188.57M	200.50M	134.76M	125.14M
	Stockholders Equity
33.10M	67.83M	138.18M	117.74M	185.40M	238.56M
Cash Flow		Free Cash Flow
-109.57M	-109.45M	-125.54M	-118.06M	-65.75M	-100.99M
	Operating Cash Flow
-104.58M	-104.50M	-105.36M	-73.10M	-10.53M	-63.97M
	Investing Cash Flow
-5.57M	23.48M	34.03M	-44.96M	-61.72M	-37.02M
	Financing Cash Flow
57.52M	54.53M	84.02M	95.20M	1.71M	82.73M

Meiragtx Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 6.63 is above the 20-day moving average (MA) of 5.63, above the 50-day MA of 5.77, and above the 200-day MA of 5.89, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 62.52 is Neutral, neither overbought nor oversold. The STOCH value of 75.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.

Meiragtx Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	61 Neutral	$538.44M	―	-75.39%	―	-35.92%	-62.11%
MGTX	59 Neutral	$532.82M	―	-216.14%	―	203.23%	-80.71%
TBPH	55 Neutral	$534.51M	―	-31.46%	―	6.11%	-37.79%
QURE	54 Neutral	$839.84M	―	-241.16%	―	6.30%	29.17%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
AKBA	49 Neutral	$934.98M	―	91.25%	―	-17.75%	-19.17%
KROS	46 Neutral	$553.99M	―	0.71%	―	91657.69%	97.21%

Meiragtx Holdings Corporate Events

MeiraGTx Holdings Receives FDA RMAT Designation for AAV-GAD

On May 9, 2025, MeiraGTx Holdings announced that the FDA granted RMAT designation to AAV-GAD for treating Parkinson’s disease, based on positive data from clinical studies. This designation facilitates accelerated approval processes and highlights the potential of AAV-GAD as a one-time treatment, offering significant benefits for Parkinson’s patients not adequately controlled by existing medications.

MeiraGTx Holdings Signs New Lease in New York

On March 31, 2025, MeiraGTx, LLC, a subsidiary of MeiraGTx Holdings plc, entered into a lease agreement with ARE-East River Science Park, LLC for laboratory and office space in New York, NY. The lease is set to commence between July 1 and August 1, 2025, with an initial term of seven years and seven months, and includes an option for a five-year extension. The agreement involves a base rent of $111 per square foot per year, with scheduled annual increases, and a landlord contribution for construction and improvements. Additionally, MeiraGTx has decided to accelerate the termination of its existing sublease with ImClone Systems, LLC, which will now end around August 31, 2025, instead of the originally scheduled October 31, 2026.